Literature DB >> 18563296

Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.

Thomas W Flaig1, Fernando J Kim, Francisco G La Rosa, Kathryn Breaker, Jonathan Schoen, Paul D Russ.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18563296     DOI： 10.1007/s10637-008-9146-z

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  14 in total

1.  Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity.

Authors:  Timothy R Asmis; Ki Y Chung; Jerrold B Teitcher; David P Kelsen; Manish A Shah
Journal:  Invest New Drugs       Date:  2007-10-26       Impact factor: 3.850

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

4.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

Authors:  Agustin A Garcia; Hal Hirte; Gini Fleming; Dongyun Yang; Denice D Tsao-Wei; Lynda Roman; Susan Groshen; Steve Swenson; Frank Markland; David Gandara; Sidney Scudder; Robert Morgan; Helen Chen; Heinz-Josef Lenz; Amit M Oza
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

5.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

6.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

7.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Pneumatosis intestinalis: a review.

Authors:  Y Heng; M D Schuffler; R C Haggitt; C A Rohrmann
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

10.  Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.

Authors:  Jhanelle Gray; John Murren; Anupama Sharma; Scott Kelley; Frank Detterbeck; Gerold Bepler
Journal:  J Thorac Oncol       Date:  2007-06       Impact factor: 15.609
View more
  15 in total

1.  Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.

Authors:  Romain Coriat; Stanislas Ropert; Olivier Mir; Bertrand Billemont; Stanislas Chaussade; Pierre-Philippe Massault; Benoit Blanchet; Olivier Vignaux; François Goldwasser
Journal:  Invest New Drugs       Date:  2010-06-05       Impact factor: 3.850

2.  Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.

Authors:  Yoshinori Hoshino; Hirotoshi Hasegawa; Yoshiyuki Ishii; Takashi Endo; Hiroki Ochiai; Koji Okabayashi; Gou Kaneko; Shuji Mikami; Makio Mukai; Mototsugu Oya; Yuko Kitagawa
Journal:  Int J Clin Oncol       Date:  2011-09-17       Impact factor: 3.402

3.  Pneumatosis cystoides intestinalis: case report and review of literature.

Authors:  Marco Di Pietropaolo; Margherita Trinci; Carlo Giangregorio; Michele Galluzzo; Vittorio Miele
Journal:  Clin J Gastroenterol       Date:  2019-06-03

4.  Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects.

Authors:  Cynthia Liu; Rajan Amin; Anusha S Thomas; Yinghong Wang; Malek Shatila; Nicholas Short; Mehmet Altan; Amishi Shah; Omar Alhalabi; Pablo Okhuysen
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-28       Impact factor: 4.322

5.  Gastrointestinal sarcoidosis associated with pneumatosis cystoides intestinalis.

Authors:  Hussein Rahim; Mubashir Khan; Jay Hudgins; Kevin Lee; Lei Du; Louis Amorosa
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

Review 6.  Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies.

Authors:  Akihito Fujimi; Hiroki Sakamoto; Yuji Kanisawa; Shinya Minami; Yasuhiro Nagamachi; Naofumi Yamauchi; Soushi Ibata; Junji Kato
Journal:  Clin J Gastroenterol       Date:  2016-09-16

Review 7.  Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.

Authors:  Maudy Walraven; Petronella O Witteveen; Martijn P J Lolkema; R van Hillegersberg; Emile E Voest; H M W Verheul
Journal:  Angiogenesis       Date:  2010-12-29       Impact factor: 9.596

8.  Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma.

Authors:  Joo Young Lee; Hye-Suk Han; Sung-Nam Lim; Young Kwang Shim; Yong Hyeok Choi; Ok-Jun Lee; Ki Hyeong Lee; Seung Taik Kim
Journal:  BMC Cancer       Date:  2012-03-10       Impact factor: 4.430

Review 9.  Pneumatosis cystoides intestinalis associated with sunitinib and a literature review.

Authors:  Yong Suk Lee; Jae Joon Han; Si-Young Kim; Chi Hoon Maeng
Journal:  BMC Cancer       Date:  2017-11-09       Impact factor: 4.430

10.  Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma.

Authors:  Takaaki Inoue; Hidefumi Kinoshita; Yoshihiro Komai; Takashi Kawabata; Gen Kawa; Yoshiko Uemura; Tadashi Matsuda
Journal:  World J Surg Oncol       Date:  2012-08-20       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.